Patents by Inventor Maria Fàtima BOSCH TUBERT

Maria Fàtima BOSCH TUBERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOWN-REGULATION OF ENDOGENOUS GENES
    Publication number: 20240107988
    Abstract: Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.
    Type: Application
    Filed: January 27, 2022
    Publication date: April 4, 2024
    Applicants: UNIVERSITAT AUTÒNOMA DE BARCELONA, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Maria Fátima BOSCH TUBERT, Verónica JIMENEZ CENZANO, Miquel GARCIA MARTINEZ, Estefanía CASANA LORENTE, Martin Matthias HRABE DE ANGELIS, Gerhard Kurt Herbert PRZEMECK, Anna-Lena AMEND
  • Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders
    Publication number: 20230201306
    Abstract: Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a central nervous system (CNS) disorder or disease, or a condition associated therewith.
    Type: Application
    Filed: May 26, 2021
    Publication date: June 29, 2023
    Applicant: Universitat Autònoma de Barcelona
    Inventors: Maria Fatima Bosch Tubert, Veronica Jiménez Cenzano, Ivet Elias Puigdomenech, Ignasi Grass Costa, Claudia Jambrina Pallarés, Victor Sacristan Fraile
  • METHODS FOR THE MANUFACTURE OF RECOMBINANT VIRAL VECTORS
    Publication number: 20220186255
    Abstract: The present invention relates to methods for the production of high titer recombinant viral vectors, more particularly recombinant AAV vectors, so that the methods can be effectively employed on a scale that is suitable for the practical application of gene therapy techniques.
    Type: Application
    Filed: March 26, 2020
    Publication date: June 16, 2022
    Inventors: Francesc GODIA-CASABLANCAS, Maria-Fàtima BOSCH-TUBERT, Miguel GARCIA-MARTINEZ, Laura CERVERA-GRACIA, Xavier LEON-MADRENAS, Maria MOLAS-LAPLANA, Sonia GUTIERREZ-GRANADOS
  • RECOMBINANT VECTORS FOR THE LONG TERM TREATMENT OF MUCCHOPOLYSACHARIDOSIS
    Publication number: 20220042043
    Abstract: The present invention provides new pharmaceutical co positions for the tong term treatment of diseases and specially, for use as tong term treatment of mucopolysaccharidoses type IIIA.
    Type: Application
    Filed: December 19, 2019
    Publication date: February 10, 2022
    Inventors: Maria-Fàtima BOSCH-TUBERT, Sara MARCO-COSTA, Adelaida MORTE-PEREZ, Carlos-Ramón PLATA-SALAMAN
  • ANIMAL MODEL OF MUCOPOLYSACCHARIDOSES TYPE IVA
    Publication number: 20220007621
    Abstract: The present invention provides a new animal model for mucopolysaccharidosis type lVA or Morquio A syndrome and to methods of generating the animal model and uses thereof.
    Type: Application
    Filed: November 14, 2019
    Publication date: January 13, 2022
    Inventors: Maria-Fàtima BOSCH-TUBERT, Joan BERTOLIN-GALVEZ, Miguel GARCIA-MARTINEZ, Victor SANCHEZ-CLARES, Anna-Maria PUJOL-ALTARRIBA
  • Fibroblast growth factor 21 (FGF21) gene therapy
    Publication number: 20210386870
    Abstract: Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS).
    Type: Application
    Filed: November 26, 2019
    Publication date: December 16, 2021
    Applicant: Universitat Autònoma de Barcelona
    Inventors: Maria Fàtima Bosch Tubert, Verónica Jiménez Cenzano, Ivet Elias Puigdomènech, Albert Ribera Sánchez, Ignasi Grass Costa
  • ADENOASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSES TYPE IV A
    Publication number: 20210214695
    Abstract: The present invention provides new polynucleotide sequences, adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidosis type IVA or Morquio A syndrome.
    Type: Application
    Filed: May 27, 2019
    Publication date: July 15, 2021
    Inventors: Maria Fàtima BOSCH TUBERT, Victor SANCHEZ CLARES, Albert RIBERA SANCHEZ, Virginia A. HAURIGOT
  • Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
    Patent number: 10617771
    Abstract: The present invention provides new Adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type II.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 14, 2020
    Assignees: UNIVERSITAT AUTÓNOMA DE BARCELONA, ESTEVE PHARMACEUTICALS, S.A.
    Inventors: Maria Fàtima Bosch Tubert, Virginia Areba Haurigot, Sandra Motas Mallol
  • ADENOASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSES
    Publication number: 20180169272
    Abstract: The present invention provides new Adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type II.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 21, 2018
    Inventors: Maria Fàtima BOSCH TUBERT, Virginia AREBA HAURIGOT, Sandra MOTAS MALLOL